Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease. is a PHASE2 clinical asset sponsored by Stanford University in Alzheimer Disease. SEO and diligence focus: Bumetanide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.